ARTICLE | Product Development
Bingham on U.K.’s flexible surge capacity in COVID-19 as foundation for future: a BioCentury audio interview
U.K. vaccine head says NHS network, national registry and manufacturing expansion central to fighting the good fight in the pandemic
September 7, 2020 11:16 PM UTC
Kate Bingham expects that manufacturing infrastructure being created in the U.K. will make the country far better prepared for future outbreaks, and that closer working relationships between drug developers and regulators, as well as among pharmas and biotechs, will endure.
In an audio interview for BioCentury’s annual Back to School issue, Bingham outlined investments in vaccine and cell and gene therapy manufacturing capacity that will give the U.K. surge capacity to cope with future outbreaks and commercial capabilities for less stressful times. She also discussed ways the U.K. is implementing its NHS network of hospitals and national registry to combat the pandemic. ...